

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your



Section 1. Identifying Inform	nation						
1. Given Name (First Name) Glen	2. Surname (Last Name) Weiss				3. Date 29-May-2019		
4. Are you the corresponding author?	are you the corresponding author?						
5. Manuscript Title Role and room for biomarkers in non-s	mall cell lu	ıng cancer					
6. Manuscript Identifying Number (if you k	now it)						
Section 2. The Work Under C			1.00				
The Work Under C	onsidera	ition for P	ublication				
Did you or your institution at any time rece any aspect of the submitted work (including statistical analysis, etc.)?	g but not li	mited to gran	nts, data monitoring	_	•		
Are there any relevant conflicts of inter If yes, please fill out the appropriate inf			No u bayo moro than	ono onti	ty proce the "ADD" button to add	d a row	
Excess rows can be removed by pressir			u nave more triai	i one enti	ty press the ADD button to aut	Jaiow.	
Name of Institution/Company	Grant ?	Personal Fees?	Non-Financial Support?	Other?	Comments		
GlaxoSmithKline	√				to institution		
fizer	√				to institution		
ncyte	√				to institution		
Asana	✓				to institution		
Macrogenics	✓				to institution		
Agenus	√				to institution		
Circulogene		✓		✓	ownership interest		
Paradigm Diagnostics		✓					
Angiex		✓					
Bex Medical Analytics		✓					



Section 3.	Relevant fin	ancial activitie	s outside t	the submitted	work.		
of compensation	n) with entities a I +" box. You sho evant conflicts o	s described in thould report relation of interest?	e instructior onships tha Yes	ns. Use one line fo	or each er	cial relationships (regardless of amountity; add as many lines as you need e 36 months prior to publication.	
Name of Entity		Grant	Personal Fees?	Non-Financial Support?	Other?	Comments	
GLG			✓				
Guidepoint Global			✓				
Imaging Endpoints II			✓				
lgnyta			✓				
Pfizer			✓				
IDEA Pharma			✓				
Cambridge Healthted	ch Institute				✓	travel and accommodation expenses	
Tesaro					✓	travel and accommodation expenses	
GlaxoSmithKline					✓	travel and accommodation expenses	
Section 4. Intellectual Property Patents & Copyrights							
Do you have any If yes, please fill o Excess rows can	out the appropr	ate information	below. If you	•		work? Yes No No ity press the "ADD" button to add a r	ow.
Paten	t?	Pending?	ed? Licens	ed? Royalties?	License	ee? Comments	
PCT/US2011/020612						small cell lung cancer	



Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of ncing, what you wrote in the submitted work?
	wing relationships/conditions/circumstances are present (explain below): tionships/conditions/circumstances that present a potential conflict of interest
	nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Weiss reports grants from GlaxoSmithKline, grants from Pfizer, grants from Incyte, grants from Asana, grants from Macrogenics, grants from Agenus, personal fees and other from Circulogene, personal fees from Paradigm Diagnostics, personal fees from Angiex, personal fees from IBex Medical Analytics, during the conduct of the study; personal fees from GLG, personal fees from GlaxoFrom GlaxoSmithKline, outside the submitted work; In addition, Dr. Weiss has a patent PCT/US2011/020612 issued.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.